



2017-18 Mississippi Division of Medicaid Synagis® Prior Authorization Criteria*

Beneficiaries must meet at least one of the bullet point criteria for age at the beginning of the RSV season: Nov 1, 2017

Age ≤ 1 year at start of RSV season and one of the following:

- Prematurity of ≤ 28 weeks 6 days gestation
- Documentation of **chronic lung disease (CLD)** of prematurity (defined as gestational age of 29 weeks 0 days – 31 weeks 6 days **AND** requirement for oxygen >21% or chronic ventilator therapy for at least the first 28 days after birth).
- Documentation of **hemodynamically significant CHD AND** one of the following:
 - (1) **acyanotic heart disease** receiving medication for congestive heart failure **AND** will require cardiac surgery.
 - (2) **moderate to severe pulmonary** hypertension.
 - (3) Documentation of **cyanotic heart disease** through consultation with pediatric cardiologist.
- Documentation of **congenital abnormalities of the airway OR neuromuscular disease** that impairs the ability to clear secretions from the upper airway because of ineffective cough.
- Documentation of **cystic fibrosis AND** clinical evidence of CLD (defined as gestational age of 29 weeks 0 days – 31 weeks 6 days **AND** requirement for oxygen >21% for at least the first 28 days after birth) **OR** nutritional compromise.
- Documentation of **profound immunocompromise** (includes, but is not limited to, patients undergoing stem cell transplantation, chemotherapy) during the RSV season.

Age 12 – 24 months at start of RSV season and one of the following:

- Documentation of **chronic lung disease (CLD)** of prematurity (defined as gestational age ≤ 31 weeks 6 days **AND** requirement for oxygen >21% or chronic ventilator therapy for at least the first 28 days after birth) **AND** required continued medical support (defined as chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) during the 6-month period before the RSV season.
- Documentation of **cystic fibrosis AND** one of the following:
 - (1) manifestations of **severe lung disease** (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest radiography or chest computed tomography that persists when stable).
 - (2) weight for length < 10th percentile.
- Documentation of **profound immunocompromise** (includes, but is not limited to, patients undergoing stem cell transplantation, chemotherapy or organ transplants) during the RSV season.

Coverage limitations:

- PA requests for Synagis will be approved starting at the onset of RSV season for a maximum of up to 5 doses and a dosing interval not less than 30 days between injections. PA requests will be accepted starting October 9, 2017 for dates of service starting November 1, 2017.
- Synagis® will not be authorized for administration prior to Nov 1, 2017. Synagis® dosing authorizations will extend for the recommended number of doses **OR** until the end of epidemic RSV season as defined by CDC - whichever occurs first. Monthly prophylaxis should be discontinued for any infant or young child who experiences a breakthrough RSV hospitalization.

NOTES:

- Prophylaxis in infants with Down Syndrome is not recommended without the presence of one of the criteria listed above.

* American Academy of Pediatric Committee on Infectious Diseases and Bronchiolitis Guidelines Committee. Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. *Pediatrics*. Available at <http://pediatrics.aappublications.org/content/early/2014/07/23/peds.2014-1665>.

SUBMISSION AND/OR APPROVAL OF A DRUG PRIOR AUTHORIZATION REQUEST DOES NOT GUARANTEE MEDICAID PAYMENT FOR PHARMACY PRODUCTS OR THE AMOUNT OF PAYMENT. ELIGIBILITY FOR AND PAYMENT OF MEDICAID SERVICES ARE SUBJECT TO ALL TERMS AND CONDITIONS AND LIMITATIONS OF THE MEDICAID PROGRAM.

Confidentiality Notice: This communication, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply telephone (1-877-537-0722) or fax (1-877-537-0720) and destroy all copies of the original message 10/01/2017